JP2005535562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535562A5 JP2005535562A5 JP2003562155A JP2003562155A JP2005535562A5 JP 2005535562 A5 JP2005535562 A5 JP 2005535562A5 JP 2003562155 A JP2003562155 A JP 2003562155A JP 2003562155 A JP2003562155 A JP 2003562155A JP 2005535562 A5 JP2005535562 A5 JP 2005535562A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- c5ar
- binding
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35096102P | 2002-01-25 | 2002-01-25 | |
| PCT/AU2003/000084 WO2003062278A1 (en) | 2002-01-25 | 2003-01-24 | MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009271989A Division JP5202501B2 (ja) | 2002-01-25 | 2009-11-30 | 抗Ｃ５ａＲ抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005535562A JP2005535562A (ja) | 2005-11-24 |
| JP2005535562A5 true JP2005535562A5 (https=) | 2006-02-23 |
| JP4559081B2 JP4559081B2 (ja) | 2010-10-06 |
Family
ID=27613447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003562155A Expired - Lifetime JP4559081B2 (ja) | 2002-01-25 | 2003-01-24 | 抗Ｃ５ａＲ抗体及びその使用 |
| JP2009271989A Expired - Lifetime JP5202501B2 (ja) | 2002-01-25 | 2009-11-30 | 抗Ｃ５ａＲ抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009271989A Expired - Lifetime JP5202501B2 (ja) | 2002-01-25 | 2009-11-30 | 抗Ｃ５ａＲ抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8071096B2 (https=) |
| EP (2) | EP1476469B1 (https=) |
| JP (2) | JP4559081B2 (https=) |
| CN (2) | CN102659945B (https=) |
| AU (3) | AU2003202297C1 (https=) |
| CA (1) | CA2476773C (https=) |
| DK (1) | DK2371861T3 (https=) |
| ES (2) | ES2561828T3 (https=) |
| NZ (1) | NZ534399A (https=) |
| WO (1) | WO2003062278A1 (https=) |
| ZA (1) | ZA200406347B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071096B2 (en) | 2002-01-25 | 2011-12-06 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
| WO2004043223A2 (en) * | 2002-11-05 | 2004-05-27 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| ES2570153T3 (es) * | 2006-08-22 | 2016-05-17 | Novo Nordisk As | Anticuerpos anti-C5aR con propiedades mejoradas |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| US20100092493A1 (en) * | 2007-03-06 | 2010-04-15 | Novo Nordisk A/S | Modulation of Complement System Activation for Treatment of Bleeding-Related Inflammation |
| AU2009215846B2 (en) * | 2008-02-19 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Complement inhibitors as therapeutic agents for treatment of cancer |
| RU2010138612A (ru) * | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR |
| CA2766565A1 (en) | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| WO2011100477A2 (en) * | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| EP2468295A1 (en) | 2010-12-21 | 2012-06-27 | Affiris AG | Vaccines based on peptides of the complement protein C5a |
| DK3424953T3 (en) * | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
| ES2691092T3 (es) | 2012-08-21 | 2018-11-23 | Janssen Pharmaceutica Nv | Anticuerpos contra la risperidona y uso de los mismos |
| JP2016523829A (ja) * | 2013-05-08 | 2016-08-12 | ノヴォ ノルディスク アー／エス | Ｃ５ａｒアンタゴニストの使用 |
| CN105744996B (zh) * | 2013-11-28 | 2018-10-19 | 通用电气医疗集团生物工艺研发股份公司 | 发酵饮料的稳定 |
| CA2940319A1 (en) * | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| JP7617012B2 (ja) * | 2019-03-14 | 2025-01-17 | モルフォシス・アーゲー | Ｃ５ａＲを標的とする抗体 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| WO2022033981A1 (en) | 2020-08-12 | 2022-02-17 | Innate Pharma | Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| JPH02262599A (ja) | 1989-01-03 | 1990-10-25 | Merck & Co Inc | ヒト多形核白血球からの精製Ｃ５ａレセプター |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| US5844094A (en) | 1992-09-25 | 1998-12-01 | Commonwealth Scientific And Industrial Research Organization | Target binding polypeptide |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5480974A (en) * | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5861272A (en) | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
| JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗Ｃ５ａレセプター抗体、その製造法および用途 |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| WO1996039511A2 (en) | 1995-06-05 | 1996-12-12 | Incyte Pharmaceuticals, Inc. | A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| WO1998033908A1 (en) | 1997-01-31 | 1998-08-06 | Incyte Pharmaceuticals, Inc. | Human c5a-like receptor |
| EP0979102A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| WO2002038767A2 (en) | 2000-11-07 | 2002-05-16 | Genetics Institute, Llc. | G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| ES2389251T3 (es) | 2000-12-19 | 2012-10-24 | Altor Bioscience Corporation | Animales transgénicos que comprenden un sistema inmunitario humanizado |
| WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| CA2461917C (en) | 2001-09-27 | 2012-01-17 | Merck & Co., Inc. | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US8071096B2 (en) | 2002-01-25 | 2011-12-06 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
| EP1581648A2 (en) | 2002-09-09 | 2005-10-05 | Nura, Inc. | G protein coupled receptors and uses thereof |
| US7285269B2 (en) | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| ES2570153T3 (es) | 2006-08-22 | 2016-05-17 | Novo Nordisk As | Anticuerpos anti-C5aR con propiedades mejoradas |
| JP2010501165A (ja) | 2006-08-22 | 2010-01-21 | ジーツー インフラメイション プロプライエタリー リミテッド | 抗体の作製方法 |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| EP2203180B1 (en) | 2007-10-22 | 2012-11-21 | Merck Serono S.A. | Single ifn-beta fused to a mutated igg fc fragment |
| RU2010138612A (ru) | 2008-02-20 | 2012-03-27 | Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ C5аR |
| WO2010000864A1 (en) | 2008-07-04 | 2010-01-07 | Novo Nordisk A/S | Method for producing monoclonal antibodies |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
-
2003
- 2003-01-24 US US10/502,145 patent/US8071096B2/en active Active
- 2003-01-24 JP JP2003562155A patent/JP4559081B2/ja not_active Expired - Lifetime
- 2003-01-24 WO PCT/AU2003/000084 patent/WO2003062278A1/en not_active Ceased
- 2003-01-24 CN CN201110205361.6A patent/CN102659945B/zh not_active Expired - Lifetime
- 2003-01-24 EP EP03700693.9A patent/EP1476469B1/en not_active Expired - Lifetime
- 2003-01-24 CN CNA038069482A patent/CN1642983A/zh active Pending
- 2003-01-24 ES ES03700693.9T patent/ES2561828T3/es not_active Expired - Lifetime
- 2003-01-24 CA CA2476773A patent/CA2476773C/en not_active Expired - Fee Related
- 2003-01-24 DK DK10009060.4T patent/DK2371861T3/da active
- 2003-01-24 EP EP10009060.4A patent/EP2371861B1/en not_active Expired - Lifetime
- 2003-01-24 ES ES10009060.4T patent/ES2646792T3/es not_active Expired - Lifetime
- 2003-01-24 NZ NZ534399A patent/NZ534399A/en not_active IP Right Cessation
- 2003-01-24 AU AU2003202297A patent/AU2003202297C1/en not_active Ceased
-
2004
- 2004-08-11 ZA ZA200406347A patent/ZA200406347B/en unknown
-
2006
- 2006-01-24 AU AU2006200320A patent/AU2006200320A1/en not_active Abandoned
-
2009
- 2009-11-19 AU AU2009238340A patent/AU2009238340A1/en not_active Withdrawn
- 2009-11-30 JP JP2009271989A patent/JP5202501B2/ja not_active Expired - Lifetime
-
2011
- 2011-10-24 US US13/280,250 patent/US8221757B2/en not_active Expired - Fee Related
-
2012
- 2012-06-15 US US13/525,092 patent/US8673305B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005535562A5 (https=) | ||
| US20250145718A1 (en) | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof | |
| KR102662387B1 (ko) | B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
| JP2009517057A5 (https=) | ||
| TW201134487A (en) | Therapeutic DLL4 binding proteins | |
| JP2010501164A5 (https=) | ||
| EP3683234A1 (en) | Il-6r antibody and antigen binding fragment thereof and medical use | |
| JP2022527151A5 (https=) | ||
| JP2011526249A5 (https=) | ||
| RU2009110154A (ru) | АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ | |
| JP2019505166A5 (https=) | ||
| JP2019507580A5 (https=) | ||
| US20130274447A1 (en) | Humanized antibodies against cxcr3 | |
| CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| JP2023537958A (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| WO2005060457A2 (en) | Treatment of inflammatory bowel diseases with anti-ip-10 antibodies | |
| CN115368457A (zh) | 抗tigit抗体及其用途 | |
| JP7643727B2 (ja) | 抗－ｆｇｆ１９抗体 | |
| TW202602922A (zh) | 結合構築體(二) | |
| HK40049006B (en) | Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof | |
| HK40049006A (en) | Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof | |
| KR20250143755A (ko) | 종양 괴사 인자 수용체 효능작용 mb | |
| CA3255180A1 (en) | Pharmaceutical composition for treating or preventing cancer with low HER2 expression | |
| CN121517563A (zh) | 人源化的靶向TfR1的抗体及其应用 |